The obituary for Leah Stavenhagen follows a script the media has perfected over decades. It highlights the "bravery," the "advocacy," and the "inspiration" of a young woman taken by Amyotrophic Lateral Sclerosis at 33. It paints a picture of a relentless fighter who founded a nonprofit, "Her ALS Story," to give a voice to women diagnosed before they even hit middle age.
But if we keep reading these stories as heartwarming tributes, we are complicit in a systemic failure. For an alternative look, consider: this related article.
The standard narrative surrounding ALS is a lie. We treat it as an elderly man’s disease that occasionally, tragically, strikes the young. We act as if awareness is the bottleneck to a cure. It isn't. The bottleneck is an archaic clinical trial infrastructure and a fundamental misunderstanding of the disease's biology that prioritizes "average" patients while ignoring the outliers who actually hold the keys to the kingdom.
The Myth of the Monolith
Most people—and frankly, too many general practitioners—view ALS as a single entity. They see it as a uniform breakdown of motor neurons. This is the first and most dangerous misconception. Similar analysis on this matter has been provided by Mayo Clinic.
ALS is not a disease; it is a clinical syndrome. It is a final common pathway for dozens of different underlying biological disasters. When we lump a 28-year-old woman in with a 75-year-old man, we are sabotaging our chances of finding a treatment.
In young-onset ALS, the genetic drivers are often distinct. We see higher frequencies of mutations in genes like FUS or SOD1. Yet, the "lazy consensus" in medical reporting suggests that because Leah Stavenhagen or Pete Frates raised millions, the "awareness" problem is solved. It’s not. Awareness is a vanity metric. What we lack is granularity.
I have seen foundations dump nine figures into "broad spectrum" research that washes out in Phase III because the patient population was too heterogeneous. If you test a drug on 100 people, and it works miracles for the five young women with a specific genetic profile but does nothing for the 95 older men with sporadic ALS, the trial is labeled a failure. The drug is scrapped. The five women die. This is the "statistical massacre" happening in neurology every single day.
Stop Humanizing the Patient and Start Analyzing the Pathology
The media loves the "human interest" angle. They want to talk about Leah's wedding, her travels to Paris, and her "indomitable spirit." While that honors her memory, it does nothing to prevent the next 25-year-old from losing their ability to breathe.
If we want to actually honor these advocates, we need to stop asking "How did they live with the disease?" and start asking "Why did the system fail to provide them with N-of-1 trial access?"
We operate under a regulatory framework designed for the 20th century. The FDA's gold standard—the randomized controlled trial (RCT)—is a death sentence for someone with a three-year life expectancy.
- The Placebo Problem: In a disease with a 100% fatality rate, giving a patient a sugar pill is ethically bankrupt.
- The Slow Onset: By the time a young patient is diagnosed, they have often lost 50% of their motor neurons.
- The Barrier to Entry: Most trials exclude patients who have been symptomatic for more than 18 or 24 months.
Young patients, like those Leah represented, are often misdiagnosed for a year or more because "you're too young for ALS." By the time they get the code on their chart, they are disqualified from the very trials that might save them. We are effectively punishing them for the medical community's own ignorance.
The Advocacy Trap
Leah Stavenhagen did something incredible by creating a space for young women. But we must be careful not to let "community building" become a substitute for "hostile disruption."
The current advocacy landscape is dominated by large legacy organizations that spend massive percentages of their budget on "support services" and "marketing." While ramps and wheelchairs are necessary, they are concessions to defeat.
The contrarian truth is that we should be diverting a massive portion of "support" funding into platform trials and expanded access. We need to stop treating ALS as a mystery and start treating it as a series of specific, solvable engineering problems.
If you are a young person diagnosed today, your "advocacy" shouldn't just be about sharing your story on Instagram. It should be about demanding Right to Try enforcement and aggressive, off-label use of experimental antisense oligonucleotides (ASOs).
The Data We Are Ignoring
We are obsessed with the "Ice Bucket Challenge" legacy, but we rarely talk about the data silos.
Every time a patient like Leah dies, a wealth of biological data disappears with them. Because of privacy laws and a lack of centralized "living biobanks," we are losing the battle one patient at a time.
Imagine a scenario where every patient with young-onset ALS was required—and incentivized—to contribute real-time biometric data, genomic sequencing, and regular CSF samples to a global, open-source database. Instead, we have proprietary data owned by pharmaceutical companies that would rather let a drug sit on a shelf than share "negative results" with a competitor.
The "competitor" isn't another drug company. The competitor is the clock.
Why "Hope" is a Productivity Killer
In the wake of deaths like Leah’s, the sentiment is always "We must keep hope alive."
Hope is not a strategy. Hope is what you rely on when you have no agency. We don't need hope; we need hostility. We need patients and families who are willing to break the "polite advocate" mold and start demanding that the NIH and FDA treat ALS with the same wartime urgency we saw during the 2020 pandemic.
We saw what happens when the world decides a disease is an existential threat. Regulations vanish. Funding is infinite. Timelines compress from decades to months. Why is ALS granted the luxury of a "slow and steady" research pace? Because the body count is spread out? Because it hits "only" 30,000 Americans at a time?
If you think the current rate of progress is acceptable, you are part of the problem.
The Hard Truth About Young-Onset
The reason young-onset cases are so devastating isn't just the "lost potential." It's that the disease in younger bodies is often more aggressive, more localized, and more resistant to the current crop of approved "stabilizers" like Riluzole.
Riluzole offers, on average, an extra two to three months of life. For a 30-year-old, that is an insult. Yet, it remains the baseline for care.
We need to stop celebrating the "approval" of drugs that offer marginal gains and start penalizing the failure to innovate. We are currently incentivizing "me-too" drugs—slight variations on existing mechanisms—because they are safer bets for investors.
The Actionable Pivot
If you want to honor Leah Stavenhagen, stop donating to general "awareness" funds.
- Fund "N-of-1" Research: Support organizations that focus on personalized medicine and individual genetic interventions.
- Demand Regulatory Reform: Pressure the FDA to allow "historical controls" in ALS trials so that no patient ever receives a placebo again.
- Genomic Sovereignty: If you are a patient, demand your full sequence and own your data. Don't let it be locked in a hospital's basement.
The "brave advocate" narrative is a comfort to the healthy. It makes the observer feel like something is being done. But Leah Stavenhagen shouldn't have had to be a "brave advocate." She should have been a patient in a system that moved as fast as her disease did.
She died because the bureaucracy is slower than the biology. Until we dismantle the way we fund, test, and talk about this disease, every "tribute" is just a distraction from the ongoing massacre of the young.
Stop admiring the struggle. Start hating the status quo.
